BSD Medical Adds a Powerful Punch to Cervical Cancer Treatment
SALT LAKE CITY, July 30 /PRNewswire-FirstCall/ -- BSD Medical Corp. (BULLETIN BOARD: BSDM) today announced that researchers in six medical centers in the United States and Europe have reported complete remission in 54 of 63 patients (86%) with advanced cervical cancer when hyperthermia therapy was added to chemotherapy and radiation.
BSD is the leading developer of systems used for hyperthermia therapy. This equipment uses focused microwave energy to elevate cancerous tissue to fever-level temperatures.
The newly reported results are the basis for more extensive research being planned involving hyperthermia with combined radiation and chemotherapy in treating cervical cancer.
Four medical centers from the Netherlands, one from Norway, and Duke University from the United States have thus-far participated in the study.
Dr. A. M. Westermann of the Academic Medical Center, Amsterdam was the lead author who presented the results at this year's American Society of Clinical Oncology (ASCO) conference held in Chicago.
The effective use of hyperthermia in combination with radiation to boost complete remission and survival from advanced cervical cancer has already been demonstrated in a landmark phase III clinical trial published in the Lancet in 2000.
This clinical trial involving 10 centers showed an 83% complete response (remission) for patients receiving both hyperthermia and radiation, as compared 57% for those receiving radiation alone.
The survival rate after three years was almost double for the patient group receiving combined radiation and hyperthermia.
One outcome of further research with the three combined therapies could be that adding chemotherapy to radiation and hyperthermia may not significantly improve results as compared to treatment with hyperthermia and radiation alone.
Based on the new report, the rate of cancer remission would appear to be similar for advanced cervical disease, with or without chemotherapy.
Further, based on studies involving chemotherapy and radiation published in 1999, the boost in survival rate when chemotherapy is added to radiation is similar to the survival increase resulting when hyperthermia is added to radiation.
In the trade-off, the much lower toxicity expected from hyperthermia could become the deciding factor in future cancer treatment.
The possible outcome driving further research, however, is that combining hyperthermia, radiation and chemotherapy could produce a survival improvement better than any before seen.
This "super therapy" could therefore become the future of cervical cancer treatment. That prospect is based on the fact that hyperthermia is used both to oxygenate tumors, improving radiation response, and to increase tumor blood flow, improving chemotherapy drug delivery into the cancer.
Hyperthermia therefore enhances both companion therapies while also killing cancer directly itself.
BSD Medical Corporation (BSDM) is the leading developer and manufacturer of hyperthermia systems for cancer therapy and pioneered the non-surgical treatment of benign diseases of the prostate using microwave energy. For additional information about BSD, visit www.bsdmc.com .
Statements contained in this press release that are not historical facts are forward looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's filings with the Securities and Exchange Commission) that could cause actual results to differ materially from estimated results.
Source: BSD Medical Corp.
CONTACT: Hyrum A. Mead of BSD Medical Corp., +1-801-972-5555, or fax,
Web site: http://www.bsdmc.com/
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.